icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Anemia had No Effect on Efficacy Outcomes in Treatment-na´ve Patients Who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies
 
 
  Reported by Jules Levin
EASL 2011 Berlin Germany March 30-April 3
 
MS Sulkowski1*, R Reddy2, NH Afdhal3, AM Di Bisceglie4, S Zeuzem5, F Poordad6, L Bengtsson7, CI Wright7, RS Kauffman7, N Adda7 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Pennsylvania School of Medicine, Philadelphia, PA, 3Beth Israel Deaconess Medical Center, Boston, MA, 4Saint Louis University School of Medicine, Saint Louis, MO, USA, 5Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany, 6Cedars-Sinai Medical Center, Los Angeles, CA, 7Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA.

EASL1.gif

BACKGROUND
· Telaprevir (TVR, T) is an orally bioavailable, specifically targeted antiviral drug for hepatitis C virus (HCV) that potently and selectively inhibits the HCV NS3·4A protease.1,2
 
· TVR in combination with peginterferon alfa-2a and ribavirin (PR) has been studied in treatment-na´ve patients and improved sustained virologic response (SVR) rates, compared with PR alone.3,4,5
 
· ADVANCE was a randomized, placebo-controlled, Phase 3 clinical trial that evaluated efficacy and safety of TVR in combination with PR in chronic HCV genotype 1-infected treatment-na´ve patients.5
 
· ILLUMINATE was an open-label, randomized, non-inferiority Phase 3 clinical trial that evaluated efficacy and safety of 24 weeks of TVR-based treatment versus 48 weeks in chronic HCV genotype 1-infected treatment-na´ve patients who achieved extended rapid virologic response (eRVR, undetectable HCV RNA at weeks 4 and 12).6
 
· In this retrospective pooled analysis, we investigated efficacy outcomes based on anemia and ribavirin dose reductions.

EASL2.gif

EASL3.gif

Pooled Analysis
· Patients who received 12 weeks telaprevir with either a total of 24 weeks or 48 weeks of PR were pooled from ADVANCE and ILLUMINATE and compared to patients who received PR from ADVANCE.
 
· Patients who took erythropoietin stimulating agents (n=12 in T12PR, n=4 in PR) and did not have a hemoglobin measurement at baseline were excluded. · Anemia was defined as hemoglobin levels <10 g/dL.
 
· Ribavirin dose interruptions/modifications of <7 consecutive days wereconsidered a dose reduction.
 
· Ribavirin dose interruptions/modifications >7 consecutive days were considered a dose interruption.

EASL4.gif

BMI = Body-mass index; genotype determined by LiPA 5'UTR assay *Race and ethnicity were self-reported and were not mutually exclusive Includes American Indian or Alaska Native, Native Hawaiian, or Other Pacific Islander and those who were not asked per local regulations
 
HCV RNA values determined by Roche COBAS® TaqMan® HCV test (Version 2.0) lower limit of detection 25 IU/mL; (HCV RNA values lower than 25 IU/milliliter were reported as either less than 25 IU/milliliter detectable or undetectable)

EASL5.gif

EASL6.gif

EASL7.gif

References
 
1. Lin K, et al. Antimicrob Agents Chemother 2004;40:4784-4792.
 
2. Perni RB, et al. Antimicrob Agents Chemother 2006;50:899-909.
 
3. McHutchison JG, et al. N Engl J Med 2009;360:1827-1838. Erratum [N Engl J Med 2009; 361:1516]
 
4. HÚzode C, et al. N Engl J Med 2009;360:1839-1850.
 
5. Jacobson IM et al. Hepatol, 2010, 52(4): Suppl 427A. Abstract #211
 
6. Sherman KE et al. Hepatol, 2010, 52(4): Suppl 401A. Abstract #LB2